期刊
EUROPEAN JOURNAL OF IMMUNOLOGY
卷 52, 期 4, 页码 656-668出版社
WILEY
DOI: 10.1002/eji.202149523
关键词
autoimmunity; B cells; neuroimmunology
类别
资金
- Projekt DEAL
B-cell modulation through targeting CD79b can achieve therapeutic effects in autoimmune diseases like MS, offering an alternative approach to complete B-cell depletion with anti-CD20 antibodies.
B cells play a major role in the pathogenesis of many autoimmune diseases like MS, rheumatoid arthritis, or systemic lupus erythematosus. Depletion of B cells with anti-CD20 antibodies is an established therapy for MS. However, total B-cell depletion will also affect regulatory B cells that are known to suppress autoimmune responses. In our studies, we describe an alternative approach based on targeting CD79b that induces only partial B-cell depletion and achieves therapeutic effects by B-cell modulation. Prophylactic and therapeutic treatment with an antibody against CD79b and also a deglycosylated variant of this antibody, lacking effector function like antibody-dependent cellular cytotoxicity or complement activation, significantly reduced the development and progression of EAE in mice. Our data show that modulation of B cells via CD79b is equally effective as almost complete B-cell depletion with anti-CD20 antibodies and may constitute an alternative approach to treat MS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据